EG24075A - Pharmaceutical suspension comprising nevirapine hemihydrate - Google Patents

Pharmaceutical suspension comprising nevirapine hemihydrate

Info

Publication number
EG24075A
EG24075A EG98398A EG98398A EG24075A EG 24075 A EG24075 A EG 24075A EG 98398 A EG98398 A EG 98398A EG 98398 A EG98398 A EG 98398A EG 24075 A EG24075 A EG 24075A
Authority
EG
Egypt
Prior art keywords
pharmaceutical suspension
nevirapine hemihydrate
nevirapine
hemihydrate
pharmaceutical
Prior art date
Application number
EG98398A
Other languages
English (en)
Inventor
Karl G Grozinger
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22006658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24075(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of EG24075A publication Critical patent/EG24075A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EG98398A 1997-08-25 1998-08-23 Pharmaceutical suspension comprising nevirapine hemihydrate EG24075A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5680397P 1997-08-25 1997-08-25

Publications (1)

Publication Number Publication Date
EG24075A true EG24075A (en) 2008-05-11

Family

ID=22006658

Family Applications (1)

Application Number Title Priority Date Filing Date
EG98398A EG24075A (en) 1997-08-25 1998-08-23 Pharmaceutical suspension comprising nevirapine hemihydrate

Country Status (38)

Country Link
US (2) US6172059B1 (sr)
EP (1) EP1019058B1 (sr)
JP (1) JP3472261B2 (sr)
KR (1) KR100426516B1 (sr)
CN (1) CN1197578C (sr)
AR (2) AR016869A1 (sr)
AT (1) ATE326971T1 (sr)
AU (1) AU742761B2 (sr)
BG (1) BG64337B1 (sr)
BR (1) BR9811994B1 (sr)
CA (1) CA2301646C (sr)
CL (1) CL2008003111A1 (sr)
CO (1) CO4970742A1 (sr)
CY (1) CY1105228T1 (sr)
CZ (1) CZ290667B6 (sr)
DE (1) DE69834655T2 (sr)
DK (1) DK1019058T3 (sr)
EG (1) EG24075A (sr)
ES (1) ES2265666T3 (sr)
HK (1) HK1027975A1 (sr)
HR (1) HRP980461B1 (sr)
HU (1) HU226063B1 (sr)
ID (1) ID21650A (sr)
IL (1) IL134185A (sr)
MY (1) MY122272A (sr)
NO (1) NO326226B1 (sr)
NZ (1) NZ503414A (sr)
PE (1) PE105799A1 (sr)
PL (1) PL192361B1 (sr)
PT (1) PT1019058E (sr)
RS (1) RS49808B (sr)
RU (1) RU2196584C2 (sr)
SA (1) SA98190680B1 (sr)
TR (1) TR200000490T2 (sr)
TW (1) TW450812B (sr)
UA (1) UA44370C2 (sr)
WO (1) WO1999009990A1 (sr)
ZA (1) ZA987623B (sr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092095A1 (en) * 2001-05-11 2002-11-21 Boehringer Ingelheim International Gmbh Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
AU2003225108A1 (en) * 2002-04-23 2003-11-10 Boehringer Ingelheim Pharmaceuticals, Inc. Method for reduction of residual organic solvent in carbomer
CA2620853A1 (en) * 2005-08-31 2007-03-08 Cipla Limited Pharmaceutical combinations containing lamivudine, stavudine and nevirapine
EP2306980A2 (en) * 2008-06-30 2011-04-13 Tibotec Pharmaceuticals Powders for reconstitution
US9273049B2 (en) * 2009-11-10 2016-03-01 North-West University Method for increasing the solubility of nevirapine
BR112012014762A2 (pt) * 2009-12-17 2016-03-29 Univ Northwest forma polimorfa de nevirapina e sua preparação

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
CA2030056C (en) * 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5571912A (en) * 1990-10-19 1996-11-05 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the preparation of 5,11-dihydro-6h-dipyrido [3,2-b:2',3'-e][1,4]diazepines
DE4403311C1 (de) * 1994-02-03 1995-04-20 Boehringer Ingelheim Kg Verfahren zur Herstellung von Nevirapine (11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4-diazepin]-6-on)

Also Published As

Publication number Publication date
BR9811994A (pt) 2000-09-05
PL338828A1 (en) 2000-11-20
MY122272A (en) 2006-04-29
YU9800A (sh) 2001-12-26
CA2301646C (en) 2008-11-18
AR016869A1 (es) 2001-08-01
CN1268055A (zh) 2000-09-27
RS49808B (sr) 2008-08-07
CA2301646A1 (en) 1999-03-04
PE105799A1 (es) 1999-11-16
AR083451A2 (es) 2013-02-27
TW450812B (en) 2001-08-21
DK1019058T3 (da) 2006-06-12
KR20010023257A (ko) 2001-03-26
CN1197578C (zh) 2005-04-20
ID21650A (id) 1999-07-08
CY1105228T1 (el) 2010-03-03
DE69834655D1 (de) 2006-06-29
EP1019058A1 (en) 2000-07-19
US6255481B1 (en) 2001-07-03
PT1019058E (pt) 2006-08-31
ATE326971T1 (de) 2006-06-15
CO4970742A1 (es) 2000-11-07
HUP0003093A2 (hu) 2001-08-28
ES2265666T3 (es) 2007-02-16
NZ503414A (en) 2002-11-26
UA44370C2 (uk) 2002-02-15
HU226063B1 (hu) 2008-04-28
WO1999009990A1 (en) 1999-03-04
HK1027975A1 (en) 2001-02-02
CZ290667B6 (cs) 2002-09-11
BG64337B1 (bg) 2004-10-29
IL134185A (en) 2005-11-20
CL2008003111A1 (es) 2009-09-11
SA98190680B1 (ar) 2006-04-04
NO20000906L (no) 2000-02-24
ZA987623B (en) 2000-03-22
NO20000906D0 (no) 2000-02-24
JP2001513564A (ja) 2001-09-04
TR200000490T2 (tr) 2000-08-21
HRP980461B1 (en) 2002-08-31
BR9811994B1 (pt) 2013-11-19
AU8777198A (en) 1999-03-16
US6172059B1 (en) 2001-01-09
EP1019058A4 (en) 2004-11-10
PL192361B1 (pl) 2006-10-31
IL134185A0 (en) 2001-04-30
AU742761B2 (en) 2002-01-10
KR100426516B1 (ko) 2004-04-13
JP3472261B2 (ja) 2003-12-02
NO326226B1 (no) 2008-10-20
HRP980461A2 (en) 1999-06-30
EP1019058B1 (en) 2006-05-24
CZ2000694A3 (cs) 2000-09-13
DE69834655T2 (de) 2006-12-14
RU2196584C2 (ru) 2003-01-20
BG104133A (en) 2000-08-31

Similar Documents

Publication Publication Date Title
PL340337A1 (en) Drugs
GB9706089D0 (en) Pharmaceutical composition
GB9700504D0 (en) Pharmaceutical compounds
SG76535A1 (en) Pharmaceutical agents
GB9726563D0 (en) Novel pharmaceutical
GB9726566D0 (en) Novel pharmaceutical
GB9815532D0 (en) Pharmaceutical suspension formulation
EG23694A (en) Novel pharmaceutical
EP1003495A4 (en) PHARMACEUTICAL COMPOUNDS
GB9716244D0 (en) Pharmaceutical compounds
GB9717444D0 (en) Pharmaceutical composition
ZA982073B (en) Pharmaceutical preparation
HUP0002455A3 (en) Gastric-retained pharmaceutical composition
GB9717428D0 (en) Pharmaceutical composition
EG24075A (en) Pharmaceutical suspension comprising nevirapine hemihydrate
ZA98300B (en) Pharmaceutical compounds
GB9717770D0 (en) Pharmaceutical composition
GB9706376D0 (en) Novel pharmaceutical
GB2321190B (en) Pharmaceutical composition
GB9726781D0 (en) Pharmaceutical composition
IL120319A0 (en) Pharmaceutical preparation
GB9723472D0 (en) Suspension means
GB9702517D0 (en) Pharmaceutical composition
GB9712097D0 (en) Pharmaceutical composition
GB9727238D0 (en) Pharmaceutical composition